Olr920 inhibitors are a class of chemical compounds that specifically target the Olfactory Receptor 920 (Olr920), which is a member of the G-protein coupled receptor (GPCR) family. These receptors are primarily involved in the detection of odor molecules, playing a crucial role in the olfactory system. Olr920, like other olfactory receptors, exhibits a seven-transmembrane domain structure, which allows it to interact with various ligands and initiate a signal transduction cascade. Inhibitors of Olr920 are designed to bind to this receptor, thereby blocking its interaction with specific odor molecules. This blockade can prevent the normal signal transduction that would typically result in the perception of a particular odor. The design and synthesis of Olr920 inhibitors often involve high-throughput screening methods and computational modeling to identify compounds that can selectively bind to and inhibit this receptor.
The chemical structure of Olr920 inhibitors varies widely, but they generally share common features that facilitate their binding to the receptor's active site. These inhibitors may contain aromatic rings, heterocycles, and various functional groups that enhance their affinity for Olr920. The development of these compounds involves extensive structure-activity relationship (SAR) studies to optimize their binding properties and ensure selectivity for Olr920 over other olfactory receptors. Researchers also employ techniques such as molecular docking and dynamic simulations to predict the interactions between the inhibitors and the receptor. Understanding the binding interactions at a molecular level helps in refining the chemical structure of these inhibitors to achieve higher specificity and potency. This class of inhibitors is of significant interest in the field of chemical biology, as it provides insights into the mechanisms of olfactory perception and the role of specific receptors in this complex sensory process.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
MEK inhibitor, can affect MAPK/ERK signaling, potentially influencing Olr920's activity. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
PI3K/mTOR inhibitor, could alter pathways involved in cell survival and growth impacting Olr920. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
mTOR inhibitor, might affect cell growth and proliferation pathways, potentially influencing Olr920. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
PI3K inhibitor, can disrupt signaling in lymphocytes, potentially affecting Olr920. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Multi-kinase inhibitor, could affect various signaling pathways including VEGF, potentially impacting Olr920. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
BCR-ABL kinase inhibitor, can alter cell proliferation and survival pathways, potentially affecting Olr920. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Inhibits multiple tyrosine kinases, could modulate pathways involved in angiogenesis and growth, affecting Olr920. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Multi-targeted receptor tyrosine kinase inhibitor, could disrupt several signaling pathways, impacting Olr920. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
BRAF inhibitor, might modulate the MAPK/ERK pathway, potentially influencing Olr920 activity. | ||||||